Oryzon Announces A New Financing Through A Convertible Bond Program For A Total Amount Up To €20 Million Over 30 Months
Oryzon Announces A New Financing Through A Convertible Bond Program For A Total Amount Up To €20 Million Over 30 Months
07/05/22, 8:00 AM
Location
madridOryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the entry into a convertible bonds financing agreement (the “Issuance Agreement”) with Nice & Green in bonds convertible into new shares for a total amount of €20 Million. The financing program consists of 4 tranches, one tranche of €8 Million and three future optional tranches of €4 Million to be drawn at the discretion of Oryzon, subject to customary conditions.
Company Info
Location
madrid, community of madrid, spain
Additional Info
Oryzon has the right to execute the redemption of any or all Notes at 3% of interest. Oryzon has one of the strongest portfolios in the field, with two LSD1 inhibitors, iadademstat and vafidemstat, in Phase II clinical trials, and other pipeline assets directed against other epigenetic targets. In addition, Oryzon has a strong platform for biomarker identification and target validation for a variety of malignant and neurological diseases. About OryzonFounded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European leader in epigenetics.